Responses
Oral Presentations
New treatments in SLE, Sjögren's and APS
OP0232 Sustained safety and efficacy over 10 years with belimumab (BEL) plus standard systemic lupus erythematosus (SLE) therapy (SOC) in patients with SLE
Compose a Response to This Article
Other responses
No responses have been published for this article.